Searched for
VALCYTE
Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patientsThe approved products is a generic therapeutic equivalent version of Roche's Valcyte.- Neutral on Dr Reddy's Laboratories with a target at Rs 3070: Credit SuisseCredit Suisse also slashed its earnings forecast as they incorporate hit in Valcyte and Vidaza.
- Sun Pharma withdraws lawsuit filed by Ranbaxy against USFDAThe lawsuit challenged FDA's revocation of Ranbaxy's tentative approvals for its generic versions of Nexium and Valcyte in the US, it added.
- India rejects Swiss drug maker Roche Patent claims on Valcyte againIndian authorities have for the second time rejected Swiss drug maker Roche’s patent claims on valganciclovir, or Valcyte, used to treat an...
- Ranbaxy loses approvals, exclusivity of two drugs in USIn November, Ranbaxy had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US.
- Dr Reddy's launches generic anti-viral tablets in US marketThe company launched Valganciclovir tablets, USP in the strength of 450 mg in the US market yesterday and the product has been approved by ...
- US court refuses Ranbaxy appeal to block ANDA nod for 2 drugsRanbaxy Laboratories had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US market.
- US court overturns Ranbaxy bid to block launch of rival generic drugsRanbaxy had sought the restraining order against Dr Reddy's Laboratories and US firm Endo International Plc
- Ranbaxy shares slump 5%; m-cap down Rs 1,072 croreShares of Ranbaxy tanked 4.15 per cent to settle at Rs 602.65 on the BSE. In intra-day, it tumbled 5.11 per cent to Rs 596.60.
- Ranbaxy sues USFDA for revoking approvals for 2 drugs; stock down by over 4%At 10:00 a.m.; the stock was at Rs 617.45, down 1.80 per cent, on the BSE. It touched a high of Rs 630 and a low of Rs 614.10 in early trad...
- Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies"FDA has no power to correct an alleged mistake it made six years ago," Ranbaxy said in the court filing dated Nov. 14 and seen by Reuters ...
- Dr Reddy's, Endo get FDA approval to launch generic ValcyteThe move comes after Ranbaxy said that FDA had stripped the company of its tentative approval to launch the first copy of the drug.
- Dr Reddy's Laboratories rallies over 6%, hits 52-week high on USFDA approvalRanbaxy recouped its intraday losses and was trading 1.2 per cent higher at Rs 661.20. It hit a low of Rs 623 and a high of Rs 664.25 in tr...
- Ranbaxy may shift key drug filings from Mohali to USConsidering its US facility is already running chock-a-bloc, analysts feel, the company may cherry-pick and transfer its first to file ANDA...
- USFDA import ban on Ranbaxy's Mohali plant to hit future launchesWith the problems with the USFDA showing no signs of abating, investors are unlikely to repose confidence in the stock any time soon.
- Ranbaxy settles patent dispute with RocheDaiichi Sankyo-owned Ranbaxy Laboratories has settled its patent dispute with Swiss major Roche for the latter’s drug valganciclovir sold u...
- Swiss co Roche loses patent on anti-viral drug ValcyteRoche, a Swiss drugmaker, lost the patent in India on its anti-viral drug Valcyte, widely used by AIDS patients, after the patent office co...
- Roche passes on Budget gain, cuts life-saving drug pricesLess than a month after duty cuts on life-saving drugs were announced in the Budget, Swiss pharma giant Roche took the first step in passin...
- SC asks Chennai patent office to hear RocheThe SC asked the Chennai patent office to hear and take a final view for all post-grant oppositions for a patent it had granted to Swiss co...
- Roche sues Cipla over Valcyte patent breachSwiss major Roche has moved the Bombay High Court (HC) against domestic major Cipla for allegedly infringing both the patent and trademark ...
Load More
